ArticleScience progress
Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveAutosomal dominant polycystic kidney disease (ADPKD) is a progressive hereditary kidney disorder with limited treatment options. Although semaglutide has demonstrated kidney-protective effects in other populations, its renal effects in ADPKD remain unknown.MethodsWe conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with ADPKD between 2000 and 2024 were identified. Patients receiving sodium-glucose cotransporter-2 inhibitors, tolvaptan, or other glucagon-like peptide-1 receptor agonists were excluded. Semaglutide users were matched 1:1 with non-users. Outcomes included creatinine-based estimated glomerular filtration rate (eGFR), stage 5 chronic kidney disease (CKD), end-stage kidney disease (ESKD), body mass index (BMI), acute kidney injury (AKI), urinary tract infection (UTI), volume depletion, and all-cause mortality.ResultsAmong 45,613 adults with ADPKD, 323 semaglutide users and 31,300 non-users met the eligibility criteria; 320 matched pairs were analyzed. At follow-up, semaglutide users had a higher mean creatinine-based eGFR than non-users (57.52 ± 28.19 vs. 50.93 ± 33.80 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.